ArticleThe Journal of antimicrobial chemotherapy2019
Intravenous catheter-related adverse events exceed drug-related adverse events in outpatient parenteral antimicrobial therapy.
Article in The Journal of antimicrobial chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Practice guidelines for outpatient parenteral antimicrobial therapy (OPAT) in Germany.Infection · 2025Guideline
- Trial
- Risk factors for peripheral intravenous catheter-related phlebitis in adult patients.Revista da Escola de Enfermagem da U S P · 2022Trial
- Comparing Self-Administered Outpatient Parenteral Antimicrobial Therapy (S-OPAT) with Alternative Delivery Models: Risk Factors for Treatment Failure and Complications in a UK Cohort.Pathogens (Basel, Switzerland) · 2026Article
- 2026 Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK.JAC-antimicrobial resistance · 2026Review
- Pills and ills: adverse events associated with oral antibiotics for prolonged durations of COpAT treatment courses.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Safety of Mini-Midline Catheters for Intravenous Antimicrobial Therapy Not Exceeding 14 Days: Treatment Completion Rate and Re-Catheterization Needs.Risk management and healthcare policy · 2026Article
- Clinical and patient-reported outcomes of self-administered outpatient parenteral antimicrobial treatment (S-OPAT): a scoping review.Infection · 2025Article
- Evaluation of the stability of tigecycline in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy.JAC-antimicrobial resistance · 2025Article
- Delivery of Outpatient Parenteral Antimicrobial Therapy (OPAT) in an Ever-Changing National Health Service (UK): Benefits, Barriers, and Opportunities.Antibiotics (Basel, Switzerland) · 2025Review
- Current practices and challenges of outpatient parenteral antimicrobial therapy: a narrative review.The Journal of antimicrobial chemotherapy · 2024Review
- [Outpatient parenteral anti-infective therapy (OPAT)].Innere Medizin (Heidelberg, Germany) · 2024Article
- The First Use of a Midline Catheter in Outpatient Pain Management.Healthcare (Basel, Switzerland) · 2024Article
- Does comorbidity index predict OPAT readmission?JAC-antimicrobial resistance · 2023Article
- Oritavancin vs Standard of Care for Treatment of Nonendovascular Gram-Positive Bloodstream Infections.Open forum infectious diseases · 2023Article
- Current Status of Outpatient Parenteral Antimicrobial Therapy in Korea: Experience of a Single University-Affiliated Acute-Care Hospital.Infection & chemotherapy · 2023Article
- The sound of blood: photoacoustic imaging in blood analysis.Medicine in novel technology and devices · 2023Article
- Impact of terminal tip location of midline catheters on catheter-related complications and indwelling duration in elderly patients.Nursing open · 2023Article
- Successful Integration of Clinical Pharmacists in an OPAT Program: A Real-Life Multidisciplinary Circuit.Antibiotics (Basel, Switzerland) · 2022Review
- Retrospective Cohort Study of the 12-Month Epidemiology, Treatment Patterns, Outcomes, and Health Care Costs Among Adult Patients With Complicated Urinary Tract Infections.Open forum infectious diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundDrug-related adverse events (AEs) are reported to be common amongst patients receiving outpatient parenteral antimicrobial therapy (OPAT). However, comparative data regarding intravenous (iv) catheter-related AEs are lacking.
objectivesTo compare drug- and iv catheter-related AEs from a large UK OPAT centre. PATIENTS AND
methodsWe reviewed 544 OPAT episodes [median (IQR) age: 57 (39-71) years, 60% male, 13% with diabetes] with a median (IQR) duration of 7 (2-18) days. Clinically significant drug- and iv catheter-related AEs were calculated as a percentage of OPAT episodes with an AE and also as AEs per 1000 iv drug/catheter days.
resultsDrug-related AEs complicated 13 (2.4%) OPAT episodes at 1.7 (95% CI 0.9-2.9) per 1000 drug days. Catheter-related AEs occurred more frequently, complicating 32 (5.9%) episodes at 5.7 (95% CI 4.2-7.9) per 1000 iv catheter days (χ2 test for difference in AE rate: P < 0.001). Non-radiologically guided midline catheters were associated with the most frequent AEs (n = 23) at 15.6 (95% CI 10.3-23.4) per 1000 iv catheter days compared with other types of iv catheters (HR 8.4, 95% CI 2.4-51.9, P < 0.004), and self-administration was associated with a higher rate of catheter-related AEs at 12.0 (95% CI 6.0-23.9) per 1000 iv catheter days (HR 4.15, 95% CI 1.7-9.1, P = 0.007).
conclusionsClinically significant iv catheter-related AEs occurred more frequently than drug-related AEs, especially when using non-radiologically guided midline catheters. Regular review of the need for iv therapy and switching to oral antimicrobials when appropriate is likely to minimize OPAT-related AEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.